Literature DB >> 15683685

Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge.

Alice N Neely1, Ian A Holder, Jeanine P Wiener-Kronish, Teiji Sawa.   

Abstract

The type III secretion system consists of secreted exoproducts and structural components, such as PcrV, and this system plays an important role in the virulence of Pseudomonas aeruginosa in burned hosts. The purpose of this study was to determine if passive anti-PcrV treatment would protect burned mice from fatal P. aeruginosa challenge, and to determine the type III exoproduct phenotype of the P. aeruginosa used as challenge strains. Antiserum was raised in rabbits. Mice were given a third degree burn, challenged with a lethal dose of P. aeruginosa, and treated with either anti-PcrV or control immunoglobulin intraperitoneally. Protection against three different pseudomonads was tested. Genotyping by PCR and phenotyping by immunoblots showed the P. aeruginosa strains to all be of the invasive type III phenotype: ExoS+ and/or ExoT+, ExoU-, ExoY+. Against all strains, the anti-PcrV treatment yielded significantly better survival (p<0.05) than the control immunoglobulin treatment. Duration of significant protection was improved by giving a second injection of PcrV antisera at 24h postburn. Hence, passive anti-PcrV immunization could protect burned mice against fatal challenge with P. aeruginosa of an invasive type III phenotype. This immunotherapy might be explored further as possible treatment for highly antibiotic resistant P. aeruginosa infections in burned hosts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15683685     DOI: 10.1016/j.burns.2004.09.002

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  26 in total

1.  Strain-dependent induction of neutrophil histamine production and cell death by Pseudomonas aeruginosa.

Authors:  Xiang Xu; Hong Zhang; Yuanlin Song; Susan V Lynch; Clifford A Lowell; Jeanine P Wiener-Kronish; George H Caughey
Journal:  J Leukoc Biol       Date:  2011-11-10       Impact factor: 4.962

2.  Presence or absence of lipopolysaccharide O antigens affects type III secretion by Pseudomonas aeruginosa.

Authors:  D K Augustin; Y Song; M S Baek; Y Sawa; G Singh; B Taylor; A Rubio-Mills; J L Flanagan; J P Wiener-Kronish; S V Lynch
Journal:  J Bacteriol       Date:  2007-01-05       Impact factor: 3.490

Review 3.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

4.  Ventilator-associated pneumonia caused by Pseudomonas aeruginosa: cap your needles!

Authors:  Alan R Hauser
Journal:  Crit Care Med       Date:  2012-08       Impact factor: 7.598

5.  A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.

Authors:  Paul Warrener; Reena Varkey; Jessica C Bonnell; Antonio DiGiandomenico; Maria Camara; Kimberly Cook; Li Peng; Jingying Zha; Partha Chowdury; Bret Sellman; C Kendall Stover
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

6.  Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV - implications for anti-PcrV immunotherapy.

Authors:  Susan V Lynch; Judith L Flanagan; Teiji Sawa; Alice Fang; Marshall S Baek; Amua Rubio-Mills; Temitayo Ajayi; Katsunori Yanagihara; Yoichi Hirakata; Shigeru Kohno; Benoit Misset; Jean-Claude Nguyen; Jeanine P Wiener-Kronish
Journal:  Microb Pathog       Date:  2010-03-06       Impact factor: 3.738

7.  Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.

Authors:  Teiji Sawa; Emi Ito; Vinh Huu Nguyen; Matthew Haight
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 8.  Progress towards recombinant anti-infective antibodies.

Authors:  Jennifer C Pai; Jamie N Sutherland; Jennifer A Maynard
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2009-01

9.  The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.

Authors:  Mao Kinoshita; Hideya Kato; Hiroaki Yasumoto; Masaru Shimizu; Saeko Hamaoka; Yoshifumi Naito; Koichi Akiyama; Kiyoshi Moriyama; Teiji Sawa
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

Review 10.  Novel strategies to combat bacterial virulence.

Authors:  Susan V Lynch; Jeanine P Wiener-Kronish
Journal:  Curr Opin Crit Care       Date:  2008-10       Impact factor: 3.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.